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Objective: The aim of this study was to investigate the effects of PRP on SAOS-2 cells in terms
of cytokine expression, cell activity and oxidative stress.
Design: Cell line SAOS-2 (1  105 cells/mL) were grown in culture medium a-MEM with 10%
FBS for 24 h and stimulated (or not) with PRP at concentrations of 3, 10 and 20%, LPS (E. coli,
10 g/mL) and IL-1b (1 mg/mL) for 24 h. The supernatant was collected and analyzed for the
expression of cytokines in a panel array, ALP using a commercial kit and NO2
 with Griess
reaction method. Also, the cells were analyzed using Western blot for RANKL and slot
blotting for nitrotyrosine expression.
Result: There were no significant differences amongst the groups in terms of NO2
, protein
nitrotyrosine content and RANKL expression. However, all stimuli increased ALP activity
and in case of PRP, it was in a dose-dependent manner ( p < 0.001). Also, all stimuli induced
an increase in cytokines and chemokines expression, but only PRP promoted an increase of
component C5, sICAM-1 and RANTES expression. Whilst IL-1 receptor antagonist (IL-1ra)
expression was down-regulated by PRP, both LPS and IL-1b caused up-regulation of this
cytokine.
Conclusions: PRP can stimulate osteoblast activity and cytokine/chemokine release, as well
as indicate some of the mediators that can (and cannot) be involved in this activation.
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Bone formation is a prerequisite for tissue regeneration after
the loss that occurs during periodontal disease and for implant
osseointegration,1 and requires the recruitment of osteoblast
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Open access under the Elsevier OA license.production of unmineralised osteoid and eventual calcifica-
tion of the extracellular matrix.2 It is a dynamic process that
involves cell-to-cell and cell-to-extracellular matrix interac-
tions, from two distinct lineages, the osteoblasts and the
osteoclasts, coordinated by various polypeptide growth
factors, such as platelet-derived growth factor (PDGF), insu-
lin-like growth factors (IGFs), transforming growth factorNESP, Rua Humaita, 1680, Araraquara, SP 14801-903, Brazil.
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biological mediators.1,3–5
The activation of platelets at the site where infection or
injury occurs, leads to the release of considerable quantities of
potent endogenous bioactive substances including growth
factors, such as vascular endothelial growth factor and
endostatin, that can accelerate or delay the healing process
respectively.6–8 Therefore, their distinctive released sub-
stances, predominantly known for their involvement in both
inflammatory/immunologic and healing process; clearly ex-
ceed an exclusive function in haemostasis and thrombosis.8
We have already demonstrated that in rats with thrombo-
cytopenia the periodontal healing process after ligature-
induced periodontitis is delayed. This process is associated,
at least in part, with decreased serum concentrations of
platelet-derived vascular endothelial growth factor (VEGF) and
endostatin.7 On the other hand, in another study8we have also
shown that the systemic administration of aspirin or
clopidogrel (both platelet activity inhibitors) attenuates the
inflammation associated with periodontitis without affecting
the bone repair process that follows the bone loss due to the
periodontal disease.8 Despite the recent advances in this field
that reveal the prominent role that platelets can play in the
inflammation and repair processes, a more comprehensive
examination of the mechanisms involved is needed.8
The clinical use of platelet-derived factors was firstly
shown by Lynch and colleagues, whom used platelet-rich
plasma (PRP) in periodontal bone defects9,10 and around
implants,11 and showed increased bone growth. PRP is an
autologous concentrated, easily obtained in which the blood
platelet concentration is above normal, with a higher
concentration of the growth factors.12 PRP has been used in
several surgical specialties, involving both bone and soft
tissues. Lately, there has been a growing interest in the use of
PRP for the treatment of many intraoral clinical conditions.
However, there has been no agreement about the advantages
derived from the adjunct of platelet concentrates to periodon-
tal surgical procedures as suggested by some reviews.13
Another important mediator of bone metabolism is nitric
oxide (NO), an L-arginine-derived free radical that plays an
important role in the host response against infection.14 High
levels of NO produced by the inducible NO synthase isoform
(iNOS) have been observed in inflammatory bone resorption15
and NO from the constitutive endothelial isoform (eNOS), the
most abundant NOS isoform in bone, seems to be important
for osteoblast function and involved in bone formation.14
Lagumdzija et al.16 showed that insulin growth factor I, which
can be found in PRP, stimulates the proliferation of osteoblasts
extracted from mouse calvaria. This stimulation was abol-
ished in cells from eNOS knock-out animals, but recovered by
a NO donor, and these results were shown to be similar in the
human osteosarcoma cell line (SAOS-2) when using a NOS
inhibitor.16
Previous studies have been investigating the mechanisms
involved in PRP stimulation in bone in vivo,4,9,10 and in vitro.17–19
However, our study brings additional evidences that contrib-
ute to the elucidation of the underlying mechanisms of PRP on
osteoblastic-like cells focusing on cytokine and chemokine
release and nitric oxide production after PRP stimulation. In
this context, the aim of this study was to investigate the effectsof PRP in an immortalized osteoblastic-like cell lineage from
osteosarcoma, SAOS-2, in terms of cytokine expression,
alkaline phosphatase activity (ALP, a marker of cell activity),
receptor activator of nuclear factor kappa-B ligand (RANKL)
expression, NO production (measured as nitrite – NO2
)
concentration and nitrotyrosine containing proteins (as an
oxidative stress marker).
2. Materials and methods
2.1. Cell culture
SAOS-2 osteoblastic cells (The Rio de Janeiro Cell Bank, Rio de
Janeiro, RJ, Brazil; CR019), derived from a primary osteogenic
sarcoma, were cultured in Alpha Minimum Essential Medium
with 100 mg/L streptomycin, 10 IE/L penicillin, and 10% foetal
bovine serum (Invitrogen, Carlsbad, CA, USA) in a number of
1  105 cells/mL in a 48 well plate for 24 h, then stimulated for
another 24 h with PRP with three different concentrations (3,
10 and 20%), LPS (E. coli, 10 mg/mL; Sigma Chem. Co., St. Louis,
MO, USA) and IL-1b (1 mg/mL; R&D Systems Inc., Minneapolis,
MN, USA).
2.2. Preparation of PRP, cell counting, viability, and
activation
The present study was approved by the Ethics in Human
Research Committee of the Araraquara School of Dentistry
(UNESP, Araraquara, SP, Brazil; CAAE – 0053.0.199.019-08). It
was conducted in full accordance with the ethical principles of
the World Medical Association Declaration of Helsinki (2002).
The volunteers were informed about the aims and methods of
this study and provided a written consent to participate.
A simple technique was used to prepare PRP using common
laboratory equipment.20 The blood samples from 5 systemi-
cally health individuals were collected into 15-mL polystyrene
tubes under sterile conditions and centrifuged at 500  g for
10 min at room temperature. The upper plasma fraction and
the buffy coat layer were carefully collected and centrifuged at
700  g for 15 min. The pellet was used as the PRP. The
samples were diluted in 1% ammonium oxalate# to haemolyze
mature erythrocytes and a Neubauer haemocytometer were
used for platelet count determination. The PRP samples were
treated with 10% calcium chloride (final concentration of 1% of
CaCl2; Sigma Chem. Co.) and bovine thrombin (50 NIH/mL
thrombin reference standard; low specific activity; Sigma
Chem. Co.) mixture to activate the platelets. The platelets were
allowed to aggregate within a few seconds of activation and
centrifuged at 5000  g for 10 min. The supernatant was
collected and immediately added to the SAOS-2 cultures. The
experiment was performed one time with 4 samples in
triplicate.
2.3. Alkaline phosphatase activity
ALP activity was determined by using a commercial kit
(Labtest, Lagoa Santa, MG, Brasil). Briefly, ALP hydrolyses
thymolphthalein monophosphate releasing thymolphthalein
in alkaline medium, and the absorbance of the blue product is
Fig. 1 – Alkaline phosphatase activity measured in
homogenates of SAOS-2 cells 24 h after being stimulated
with PRP, LPS and IL-1b (n = 4). ***p < 0.001 vs. all the
remaining (stimulated) groups.
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phate-buffered saline solution (PBS) (Invitrogen) and treated
with 1.1 mL of sodium lauryl sulphate (1 mg/mL, SDS; Sigma
Chem. Co.) for 30 min at room temperature. Fifty microliters
from each sample were added to the kit solutions according to
the manufacturer. Results were calculated as U/L and data were
expressed as ALP activity normalized by the protein concentra-
tion (measured using the method of Bradford).21,22
2.4. Western blot analysis of RANKL expression
After measurement of protein contents in the samples (using
the Bradford method [22]), the expression of RANKL receptor
was analyzed in the cells as previously described23 Immuno-
reactive bands were detected by chemiluminescence (Thermo
Scientific, Waltham, MA, USA) and their intensities were
estimated by densitometric analysis (ChemImager 5500
system, Alpha Innotech Corp., USA).
2.5. Slot blotting analysis of nitrotyrosine-containing
proteins
The presence of proteins containing 3-nitrotyrosine (NT)
residues, an index of oxidative stress and protein nitration,
was analyzed in the cells using a protein slot blotting method,
as described previously.24 Immunoreactive bands were
detected by chemiluminescence (Thermo Scientific) and their
intensities were estimated by densitometric analysis (ChemI-
mager 5500 system). Results were normalized by the band
intensity values obtained after staining with Ponceau red.
2.6. Measurement of NO2
S concentration
Nitrite concentration in the in the cell culture supernatants
was quantified by the Griess reaction method.25 Briefly, the
supernatant (100 mL) reacted at room temperature with an
equal volume of the Griess reagent (1% sulphanilamide plus
0.1% naphthylethylenedihydrochloride in 2.5% phosphoric
acid; Sigma Chem. Co.) and the absorbance of the resulting
chromophore was read at 450 nm. The samples were run in
duplicate using 96-well microtiter plates, and nitrite concen-
trations were calculated from a sodium nitrite standard curve.
2.7. Proteome profiler human cytokine array
The cell culture supernatants were analyzed with the Proteome
Profiler Human Cytokine Array Panel A Array Kit (R&D Systems
Inc.). Nitrocellulose membranes, each containing 36 different
anti-cytokine antibodies (anti-C5a, CD40 Ligand, G-CSF, GM-
CSF, GRO, I-309, sICAM-1, IFN-g, IL-1a, IL-1b, IL-1ra, IL-2, IL-4, IL-
5, IL-6, IL-8, IL-10, IL-12, p70, IL-13, IL-16, IL-17, IL-17E, IL-23, IL-
27, IL-32a, IP-10, I-TAC, MCP-1, MIF, MIP-1a, MIP-1b, Serpin E1,
RANTES, CXCL12, TNF-a, sTREM-1) in duplicate, were incubated
with the supernatant samples and a cocktail of biotinylated
detection antibodies. Any cytokine/detection antibody complex
present in the sample is bound by its cognate immobilized
capture antibody on the membrane. After washing (in order to
remove unbound material), streptavidin–horseradish peroxi-
dase and chemiluminescent detection reagents (Thermo Scien-
tific) were sequentially added. The chemiluminiscence signal ofthe membranes were captured and the intensity of each
spot was estimated by densitometric analysis (ChemImager
5500 system) after standardized preliminary image processing
for noise reduction, background subtraction and signal
enhancement.26
2.8. Statistical analysis
All data were analyzed by one-way analysis of variance and
corrected for multiple measures by the Newman-Keuls
correction. All values are reported as mean  SEM. Statistical
significance was set at 0.05.
3. Results
3.1. Alkaline phosphatase activity
As shown in Fig. 1, stimulation with PRP increased ALP activity
in SAOS-2 cells after 24 h incubation in a dose-dependent
manner (Control: 86.4  0.7, 3% PRP: 94.6  0.7, 10% PRP:
99.7  1.6 and 20% PRP: 104.1  1.1 U/mg of protein;
p < 0.001), as it was also the case for both LPS (99.8  1.1 U/
mg of protein) and IL-1b (103.1  1.0 U/mg of protein;
p < 0.001). We did not observe differences between all the
treatment groups.
3.2. Protein nitrotyrosine content, RANKL expression
and NO2
S concentration
There were no significant differences amongst the groups in
terms of either NO2
 concentration in the cell culture
supernatants (Control: 1.31  0.26, 3% PRP: 1.261  0.22, 10%
PRP: 1.37  0.32, 20% PRP: 1.19  0.32, LPS: 1.16  0.33 and IL-
1b: 1.16  0.16 M), or protein nitrotyrosine content and RANKL
expression in SAOS-2 extracts obtained 24 h after incubation
with the different stimuli (Fig. 2).
3.3. Cytokine expression
During stimulation process, multiple cytokines and chemo-
kines were secreted in SAOS-2 supernatants. As shown in
Fig. 2 – Pannel A: Nitrite concentration in supernatants collected 24 h after the stimulation of SAOS-2 cells with either PRP (3,
10 and 20%), LPS or IL-1 b. Panel B: RANKL and nitrotirosine (NT) expression in cell protein extract obtained 24 h after
stimulation of SAOS-2 cells with either PRP (3, 10 and 20%), LPS or IL-1 b. Ponceau stained bands were used as loading
control. BSA and NTBSA (nitrated bovine serum albumin) were used as negative and positive controls, respectively (n = 4).
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expression of interleukin-6 (IL-6) and plasminogen activator
inhibitor-1 (Serpin-1) when compared to the control. After PRP
stimulation, the expression of complement component C5 (C5a),
soluble Intercellular Adhesion Molecule-1 (sICAM-1) and
Regulated upon Activation, Normal T-cell Expressed, and
Secreted (RANTES) protein were up-regulated. Whilst IL-1
receptor antagonist (IL-1ra) expression was down-regulated
by PRP, both LPS and IL-1b caused up-regulation of this
cytokine. In addition, IL-1b up-regulated Granulocyte-macro-
phage colony-stimulating factor (GM-CSF), Chemokine (C-X-C
motif) ligand 1 (CXCL1), IL-ra and IL-32a (Fig. 3).
4. Discussion
Inflammatory cytokines are key mediators of osteoclastogen-
esis and osteoclast action. They are present in the bone
microenvironment in quite variable amounts, as a conse-
quence of different disease conditions. However, there is not a
general agreement about the advantages of using platelet
concentrates in periodontal surgical procedures, as stated in
the review from Del Fabbro,13 and the role of platelets in
controlling osteoblast differentiation, function, and apoptosis
is not completely clear.27
Bacterial constituents, including Gram-negative-derived
lipopolysaccharides (LPS), initiate inflammatory bone loss, asexhibited in periodontal diseases. LPS can stimulate the
expression of IL-1b, TNF-a, IL-6, and RANKL by activating the
innate immune response. In this study, we used LPS and IL-1b as
positive control based on previous studies showing that IL-1b28
and LPS29 induce osteoblast-like cells stimulation, an important
event in the etiopathogenesis of periodontal disease.
Several studies have been previously published aiming the
elucidation of the actions of PRP on osteoblastic-like cells,17–19
however the analyzed end-points and the experimental
conditions (such as incubation time and PRP concentrations)
are variable. For example, Kanno et al.19 studied the effects of
PRP at different concentrations (5 and 10%) and time points
(first analysis were made after 24 h); Ogino et al.17 stimulated
the cells with PRP for 36 and 72 h but did not analyzed the
effects on ALP; Bertoldi et al.18 studied SAOS-2 cell culture
during 19 days stimulated with 1% PRP (freshly added every 2
or 4 days) and evaluated ALP on day 21st.
In this study, instead, we focus on nitric oxide and
cytokine/chemokine production by osteoblastic-like cells.
Previous studies have already shown that PRP stimulates
the proliferation of osteoblast-like cells in a dose-dependent
manner, and that PDGF and TGF-b1, but not IGF-I, significantly
contribute to this process,17 resulting in enhanced bone
regeneration and healing activation.28
Platelet-derived growth factors initiates connective tissue
healing and activates bone regeneration, including mitogen-
esis, by increasing the number of healing cells, triggering
Fig. 3 – Panel A: Human cytokine array panel from cultured SAOS-2 cell supernatants obtained 24 h after stimulation with
PRP, LPS or IL-1b. Panel B: Pixel density plot of the analytes detected in the corresponding cytokine array (in arbitrary units).
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hand, transforming growth factor b (TGF-b), a generic growth
factor which can be produced by macrophages, fibroblasts and
specially by platelets. TGF-b acts in connective tissue repair
and regeneration; it is also a potent inhibitor of osteoclast
formation and bone resorption, allowing bone formation,30,31
triggering adjacent cells, such as pre-osteoblasts, to differen-
tiate into mature osteoblasts favouring the initiation of bone
remodelling, tissue healing, and bone mineralization.19
PRP is an easy available blood derivative that contains high
concentrations of growth factors and cytokines which, when
locally applied, increase tissue and bone repair acting on
osteoprogenitor cell recruitment, proliferation, and differentia-
tion.32 The clinical use of PRP is an entirely safe procedure,
causing no adverse events or postoperative complications.33 In
the present study, and in order to study the effects of PRP on
osteoblasts, we made use of the SAOS-2 cell line given its well-
documented characterization as a moderately to well-differen-
tiated osteoblastic cell type.34 Our results show that PRP induces
ALP activity in a concentration-dependent manner, and to an
extent comparable to those induced by either LPS or IL-1b
stimulation (Fig. 1). Since the highest activity was observed with
20% PRP, we decided to use this concentration in the experi-
ments entitled to analyze cytokine and chemokine release.
Other authors have also reported that PRP induces ALP
expression. For example, Bertoldi et al.18 showed that PRP
induces SAOS-2 proliferation and differentiation, although
repeated administration of PRP was needed in order to achieve
better results. Kanno et al.19 observed that PRP has favourableeffects, enhancing the viability of the cells in a dose-dependent
manner, ALP activity when the cells reached confluence and the
levels of procollagen type I, osteopontin, osteoprotegerin, and
core binding factor alpha 1 (cbfa1) mRNAs.19
In this study we show that, in a concentration-dependent
manner (and similarly to Ogino et al.17), PRP obtained from five
different donors increased the osteoblastic activity of SAOS-2
cells, as assessed by the increase in ALP activity. It is well
known that PRP can differ amongst donors, mainly in terms of
cell viability and platelet counts. In addition, the efficacy on
bone regeneration might be very diverse, and individual
differences in the amount of each growth factor should be
considered.19 For this reason, we made use of a 20% PRP pool in
culture medium for stimulation of the SAOS-2 cells and
further assessment of the release of pro- and anti-inflamma-
tory cytokines and chemokines into the supernatant. PRP
induced the expression of soluble intercellular adhesion
molecule-1 (sICAM-1), complement component 5a (C5a) and
RANTES, all chemokines important in bone metabolism. IL-6
expression was also increased and, according to previous
studies,35,36 can happen as result of the up-regulation of the
above mentioned chemokines.
Chemokine-regulated chemotaxis is an important attribute
of osteoblasts, by mediating their migration to sites of bone
resorption.37 Stromal cells and osteoblasts have a potential
chemotactic property in response to growth factors such as
platelet-derived growth factor (PDGF), vascular endothelial
growth factor (VEGF), insulin-like growth factor (IGFs),
transforming growth factor (TGFb) and bone morphogenetic
a r c h i v e s o f o r a l b i o l o g y 5 7 ( 2 0 1 2 ) 1 2 8 2 – 1 2 8 9 1287proteins (BMPs)38 amongst others stimuli.37 During bone
resorption, substances released from bone matrix influence
osteoblast chemotaxis, with scant reference to the possible
production of chemoattractants by osteoclasts per se.37
RANTES appears to be an important molecule for commu-
nication between osteoclasts and osteoblasts and this signal-
ling is important to osteoblast biology.37 RANTES is secreted by
bone cells and participate in osteoclastogenesis, recruiting
osteoblasts and protecting against apoptosis during the
resorptive and formative phases of bone turnover, respective-
ly. On the other hand, sICAM-1 exerts important osteotropic
effects by mediating the adhesion of osteoblasts to osteoclast
precursors, thereby facilitating osteoclast differentiation and
bone resorption.39 Lavigne at al.35 showed that sICAM-1
expression in osteoblasts obtained from patients with osteo-
arthritis and osteoporosis was higher than that observed in
normal human osteoblasts. In addition, IL-6 and PGE2 levels
were found to be significantly elevated with high ICAM-1
expression compared to low ICAM-1 expression.35
C5a, another potent chemoattractant, was also found up-
regulated in SAOS-2 cells in response to PRP, although down-
regulated by LPS or IL-1b. C5a can induce the release of
cytokines (particularly IL-6) and proteolytic enzymes, and may
thus represent an important modulator of osteoblast/osteo-
clast activities associated with bone resorption.36
More than two decades ago, Lynch et al.10 show that PDGF,
one of the most important growth factors found in PRP,
promotes new bone formation around periodontal bone
defects and stimulate a continuous layer of osteoblasts lining
the newly formed bone around periodontal bone defects in
Beagle dogs.10 Since then several clinical and experimental
studies have been performed to investigate role of PRP in bone
regeneration. Also, mature osteoclasts can produce chemo-
tactic factors, including PDGF, that attract osteoblasts and
fibroblasts towards the injured or inflamed sites thereby
promoting bone/tissue regeneration.40–42
Although we have previously shown that iNOS-derived NO
is involved in periodontitis-induced alveolar bone loss by
enhancing osteoclast differentiation and activity,15 and that
protein nitration can occur during periodontitis,23 in the
present study, no significant effects due to the different
stimuli were observed in terms of either nitrotirosine-
containing proteins in the SAOS-2 cells or nitrite (a nitric
oxide end-product) concentrations in the cell culture super-
natants (Fig. 2). These observations are supported by the study
from Da Rocha et al.43 whom using a primary human
osteoblast-like cell obtained after hip arthroplasty, showed
that the treatment with IL-1a or TNF-a (or their combination
with IFN-g) during 72 h did not result in altered NO production
or increased nitrotyrosine-containing proteins.43
As a whole, we may suggest that the effects of NO on bone
metabolism are highly dependent on the available amounts of
this mediator. NO (especially from iNOS) is involved in bone
loss by enhancing osteoclast differentiation and activity, and
its potential sources periodontium are inflammatory cells,
keratinocytes, fibroblasts, osteoclasts and blood vessels,44 but
not osteoblasts.
In addition, we did not observe any significant increase of
RANKL expression in these cells in response to the stimuli,
thus suggesting that osteoclast stimuli by the coupling ofRANKL/RANK can be done by other cells that may be involved,
such as T-cells45 and periodontal ligament fibroblasts,46 which
are also sources of RANKL.
There is a growing interest on the use of platelet concentrates
for treatment of many intraoral clinical conditions involving
bone healing. Bone loss secondary to periodontal defects is
amongst these situations; however, diverse outcomes showing
both positive47 and negative48 results have been reported to date,
probably reflecting the limited number and heterogeneity of the
available data.33 For example, in a systematic review, Del Fabbro
et al.13 report that PRP may have positive adjunctive effects when
used in combination with graft materials, but not with guided
tissue regeneration, for treatment of intrabony defects.13 In this
way, it becomes evident the need of additional research on the
efficacy of each specific therapeutic approach envolving
combination with PRP.33
In summary, from the results shown in this study, we can
conclude that in cultured SAOS-2 cells PRP stimulates
osteoblast activity and a specific cytokine/chemokine pattern
release, indicating some of the mediators that can (and
cannot) be involved in this activation. Whether these results
can be, at least partially, extrapolated to the in vivo situation, it
still remains to be determined.
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